ARVO 2024: Post hoc analysis of phase 3 trial on SB15
May 8th 2024ARVO
At this year's ARVO meeting, SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024ARVO
John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Researchers drive innovation in retinal research
May 7th 2024ARVO
A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.
ARVO 2024: Study validates ChatGPT 4.0 as potential uveitis patient resource
May 7th 2024ARVO
In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.
ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 6th 2024ARVO
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
ARVO 2024: Understanding the reading problem for patients with central vision loss
May 5th 2024ARVO
Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Vision-related activity difficulties in people diagnosed with nAMD and vision impairment
May 5th 2024ARVO
Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.
Companies begin to announce their plans for data presentations at ARVO 2024
April 24th 2024ARVO
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.
COPHy 2024: Should all patients with idiopathic intracranial hypertension have a lumbar puncture?
March 16th 2024COPHy
Andrew G. Lee, MD, outlines his stance on whether all patients with idiopathic intracranial hypertension should have a lumbar puncture, emphasizing clinical judgment and treatment strategies.
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024COPHy
The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.